BioMarin Pharmaceutical Inc.
BMRN
Health Care
2
exclusion reasons
1 theme
BioMarin Pharmaceutical Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
BioMarin Pharmaceutical Inc. conducts animal testing as a core part of its pre-clinical drug development process. The company develops and commercializes therapies for rare genetic diseases, a process that relies on animal models to assess the safety and efficacy of new treatments before human trials. This standard industry practice places the company on lists maintained by organizations like Cruelty Free Investors, which flag firms engaged in animal testing.
The company has been involved in litigation related to its intellectual property and development processes, including a 2017 patent dispute with Duke University concerning the production of a therapeutic enzyme. The case referenced teachings focused on producing human acid alpha-glucosidase (hGAA) "in the milk of transgenic nonhuman animals." While the litigation centered on patent validity, it underscores the company's historical engagement with biotechnological processes involving animal models.
BioMarin Pharmaceutical Inc. develops enzyme replacement therapies for rare genetic disorders, a process that requires animal testing for preclinical safety and efficacy data as part of regulatory submissions. The company’s own SEC filings and corporate documents consistently reference animal studies as a standard component of its product development pipeline. While BioMarin publishes a Supplier Code of Conduct stating that animal testing should minimize the numbers of animals used and refine procedures to lessen distress, and a Global Code of Business Ethics accepting responsibility for humane animal research, these policies govern the conduct of existing testing rather than eliminating it. As a pharmaceutical company whose products are subject to FDA and other global health authority approvals, BioMarin funds, commissions, and relies on animal testing to advance its clinical candidates, a practice that triggers this exclusion.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.